Search Names & Symbols
With personal love and passion we work alone and analyze our favorite shares. May not be many, but they are worth it.
The best online stock broker. Open an account today and start earning up to $1000 of IBKR Stock !
DISCLAIMER:
The financial and technical analycies presented on this website have not been performed by an Investment Services Company, nor have they been compiled by a certified analyst . It is simply a display and presentation of public data of Greek and foreign shares with informative and entertaining character.
Showing posts with label Vir Biotechnology announcments. Show all posts
Showing posts with label Vir Biotechnology announcments. Show all posts
Sunday, June 26, 2022
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
– Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International
Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals –
– Company expects to dose first patient in Part B of the Phase 2 MARCH trial by the end of June –
SAN FRANCISCO, June 25, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) clinical trial program, including results from an ongoing Phase 2 clinical trial of VIR-2218, results from an ongoing Phase 1 clinical trial of VIR-3434 and preclinical data evaluating both investigational compounds as monotherapy and in combination. Data were presented in one oral and two poster presentations at the International Liver Congress™ (ILC) 2022, the Annual Meeting of the European Association for the Study of the Liver (EASL).
Subscribe to:
Posts (Atom)